Combined-modality therapy for esophageal and gastroesophageal junction cancers

Harry H. Yoon, Michael K. Gibson

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

The optimal management of locoregional esophageal cancer is controversial. Preoperative concomitant chemoradiotherapy (two courses of cisplatin and 5-fluorouracil plus 50 Gy of radiation) may provide benefit in survival and local control compared with surgery alone and is a reasonable alternative to surgery alone in stages IIB, III, and possibly stage IVa disease. This benefit is less clear in stages I and IIA, for which surgery alone is thus a reasonable option. Preoperative chemotherapy without radiation also provides a survival benefit compared with surgery alone, but data are insufficient to conclude it is superior to preoperative chemoradiotherapy. Control of distant disease remains a problem with preoperative chemotherapy and preoperative chemoradiotherapy.

Original languageEnglish (US)
Pages (from-to)184-192
Number of pages9
JournalCurrent oncology reports
Volume9
Issue number3
DOIs
StatePublished - May 1 2007

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Combined-modality therapy for esophageal and gastroesophageal junction cancers'. Together they form a unique fingerprint.

  • Cite this